Understanding p53 functions through p53 antibodies

被引:99
作者
Sabapathy, Kanaga [1 ,2 ,3 ,4 ]
Lane, David P. [5 ]
机构
[1] Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Lab Mol Carcinogenesis, 11 Hosp Dr, Singapore 169610, Singapore
[2] Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore
[3] NUS, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore
[4] Inst Mol & Cellular Biol, 61 Biopolis Dr, Singapore 138673, Singapore
[5] ASTAR, P53 Lab p53Lab, Singapore 138648, Singapore
关键词
antibodies; conformation; mutant; p53; post-translational modifications; WILD-TYPE P53; DNA-BINDING ACTIVITY; TRANSFORMATION-RELATED PROTEIN; MUTANT-LIKE CONFORMATION; CELL-CYCLE ARREST; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; TUMOR-ANTIGEN; POSTTRANSLATIONAL MODIFICATIONS; IMMUNOCHEMICAL ANALYSIS;
D O I
10.1093/jmcb/mjz010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
TP53 is the most frequently mutated gene across all cancer types. Our understanding of its functions has evolved since its discovery four decades ago. Initially thought to be an oncogene, it was later realized to be a critical tumour suppressor. A significant amount of our knowledge about p53 functions have come from the use of antibodies against its various forms. The early anti-p53 antibodies contributed to the recognition of p53 accumulation as a common feature of cancer cells and to our understanding of p53 DNA-binding and transcription activities. They led to the concept that conformational changes can facilitate p53's activity as a growth inhibitory protein. The ensuing p53 conformational-specific antibodies further underlined p53's conformational flexibility, collectively forming the basis for current efforts to generate therapeutic molecules capable of altering the conformation of mutant p53. A subsequent barrage of antibodies against post-translational modifications on p53 has clarified p53's roles further, especially with respect to the mechanistic details and context-dependence of its activity. More recently, the generation of p53 mutation-specific antibodies have highlighted the possibility to go beyond the general framework of our comprehension of mutant p53-and promises to provide insights into the specific properties of individual p53 mutants. This review summarizes our current knowledge of p53 functions derived through the major classes of anti-p53 antibodies, which could be a paradigm for understanding other molecular events in health and disease.
引用
收藏
页码:317 / 329
页数:13
相关论文
共 159 条
[1]   Stress signals utilize multiple pathways to stabilize p53 [J].
Ashcroft, M ;
Taya, Y ;
Vousden, KH .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (09) :3224-3233
[2]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[3]   MONOCLONAL-ANTIBODIES AGAINST SIMIAN VIRUS-40 NUCLEAR LARGE T-TUMOR ANTIGEN - EPITOPE MAPPING, PAPOVA VIRUS CROSS-REACTION AND CELL-SURFACE STAINING [J].
BALL, RK ;
SIEGL, B ;
QUELLHORST, S ;
BRANDNER, G ;
BRAUN, DG .
EMBO JOURNAL, 1984, 3 (07) :1485-1491
[4]   Enhanced phosphorylation of p53 by ATN in response to DNA damage [J].
Banin, S ;
Moyal, L ;
Shieh, SY ;
Taya, Y ;
Anderson, CW ;
Chessa, L ;
Smorodinsky, NI ;
Prives, C ;
Reiss, Y ;
Shiloh, Y ;
Ziv, Y .
SCIENCE, 1998, 281 (5383) :1674-1677
[5]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[6]  
BARTEK J, 1990, ONCOGENE, V5, P893
[7]   RADIOIMMUNOASSAY OF THE CELLULAR PROTEIN P53 IN MOUSE AND HUMAN CELL-LINES [J].
BENCHIMOL, S ;
PIM, D ;
CRAWFORD, L .
EMBO JOURNAL, 1982, 1 (09) :1055-1062
[8]   Unravelling mechanisms of p53-mediated tumour suppression [J].
Bieging, Kathryn T. ;
Mello, Stephano Spano ;
Attardi, Laura D. .
NATURE REVIEWS CANCER, 2014, 14 (05) :359-370
[9]   Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 [J].
Blagosklonny, MV ;
Toretsky, J ;
Bohen, S ;
Neckers, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8379-8383
[10]   Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs [J].
Blagosklonny, MV .
LEUKEMIA, 2002, 16 (04) :455-462